Shares of GeneDx Holdings (WGS) surged 5.31% in pre-market trading following the company's release of impressive first-quarter 2025 results and an upward revision of its full-year guidance. The genetic testing company reported robust growth in its core exome and genome business, along with strategic expansions that have bolstered investor confidence.

GeneDx announced Q1 2025 revenues of $87.1 million, with exome and genome revenues growing an impressive 62% year-over-year to $71.4 million. This strong performance led the company to raise its full-year 2025 revenue guidance to $360 million to $375 million. CEO Katherine Stueland highlighted the company's third consecutive quarter of profitability and emphasized their strengthening industry-leading position in diagnosing genetic diseases.

Adding to the positive sentiment, GeneDx revealed several strategic initiatives driving future growth. These include the launch of an ultraRapid Genome Sequencing product with a 48-hour turnaround time, expansion into new clinical indications such as immune deficiency disorders, and plans to acquire Fabric Genomics to enhance AI-powered genomic interpretation capabilities. With these developments and the company's focus on integrating exome and genome testing more proactively as the standard of care, investors appear optimistic about GeneDx's growth trajectory in the evolving field of genetic diagnostics.